TGFB1 and pulmonary fibrosis: The safety and efficacy of EW-7197 has been documented in animal models, and several investigators have reported that EW-7197 safely inhibited hepatic, renal, and pulmonary fibrosis and stent-induced granulation tissue formation by blocking the TGF-β/Smad and/or reactive oxygen species (ROS) signaling pathway [15,16,26].